Relative Bioavailability of Two Different Tablet Formulations of BI 1358894 Administered in Healthy Subjects in Fasted and Fed State (an Open-label, Randomised, Single-dose, Four-period, Four-sequence Crossover Study)
Latest Information Update: 21 May 2022
At a glance
- Drugs BI 1358894 (Primary)
- Indications Borderline personality disorders; Major depressive disorder; Post-traumatic stress disorders
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 17 May 2022 Status changed from active, no longer recruiting to completed.
- 21 Mar 2022 Planned End Date changed from 28 Apr 2022 to 16 May 2022.
- 21 Mar 2022 Planned primary completion date changed from 28 Apr 2022 to 16 May 2022.